D.E. Shaw & Co
AGL icon

D.E. Shaw & Co’s Agilon Health AGL Stock Holding History

D.E. Shaw & Co’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.87M Sell
742,218
-70,235
-9% -$1.14M ﹤0.01% 2062
2025
Q4 		$14M Buy
812,453
+412,698
+103% +$8M 0.01% 1476
2025
Q3 		$10.3M Buy
399,755
+342,717
+601% +$12.9M 0.01% 1660
2025
Q2 		$3.28M Buy
57,038
+17,494
+44% +$1.4M ﹤0.01% 2357
2025
Q1 		$4.28M Buy
39,544
+24,773
+168% +$2.16M ﹤0.01% 2008
2024
Q4 		$702K Buy
14,771
+80
+0.5% +$4.84K ﹤0.01% 3419
2024
Q3 		$1.44M Buy
14,691
+7,432
+102% +$960K ﹤0.01% 2970
2024
Q2 		$1.19M Buy
7,259
+6,587
+980% +$938K ﹤0.01% 3075
2024
Q1 		$102K Buy
+672
New +$112K ﹤0.01% 4005
2022
Q4 		– Sell
-1,217
Closed -$713K – 4833
2022
Q3 		$713K Buy
+1,217
New +$729K ﹤0.01% 3823
2021
Q4 		– Sell
-14,039
Closed -$9.2M – 5353
2021
Q3 		$9.2M Buy
14,039
+5,945
+73% +$5.08M 0.01% 1574
2021
Q2 		$8.21M Buy
+8,094
New +$7.09M 0.01% 1664

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NPCM
North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's AGL Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Agilon Health (AGL) stake by 8.6% in Q1 2026, selling an estimated $1.14M and leaving 742,218 shares worth $5.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2062.

D.E. Shaw & Co first reported a position in AGL in Q2 2021 and has held it in 12 quarters since. The position peaked at $14M in Q4 2025. 97 funds tracked by Wall St. Rank hold AGL as of Q1 2026.

  • D.E. Shaw & Co held 742,218 shares of Agilon Health worth $5.87M as of Q1 2026.
  • D.E. Shaw & Co sold 70,235 Agilon Health shares in Q1 2026, an estimated $1.14M.
  • Agilon Health made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2062 holding.
  • D.E. Shaw & Co first reported a position in Agilon Health in Q2 2021 and has held it in 12 quarters since.
  • D.E. Shaw & Co's Agilon Health position peaked at $14M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Agilon Health as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.